Nova Eye Valuation
| EYE Stock | 0.15 0.01 7.14% |
Nova Eye seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Nova Eye Medical from analyzing the firm fundamentals such as Return On Equity of -0.39, profit margin of (0.38) %, and Current Valuation of 30.41 M as well as examining its technical indicators and probability of bankruptcy.
Price Book 1.5571 | Enterprise Value 30.4 M | Enterprise Value Ebitda (3.96) | Price Sales 1.5239 | Enterprise Value Revenue 1.3038 |
Overvalued
Today
Please note that Nova Eye's price fluctuation is out of control at this time. Calculation of the real value of Nova Eye Medical is based on 3 months time horizon. Increasing Nova Eye's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Nova Eye's intrinsic value may or may not be the same as its current market price of 0.15, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.15 | Real 0.14 | Hype 0.16 |
The intrinsic value of Nova Eye's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nova Eye's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nova Eye Medical helps investors to forecast how Nova stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nova Eye more accurately as focusing exclusively on Nova Eye's fundamentals will not take into account other important factors: Nova Eye Cash |
|
Nova Eye Total Value Analysis
Nova Eye Medical is currently forecasted to have takeover price of 30.41 M with market capitalization of 35.54 M, debt of 3.35 M, and cash on hands of 7.42 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Nova Eye fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
30.41 M | 35.54 M | 3.35 M | 7.42 M |
Nova Eye Investor Information
About 19.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Nova Eye Medical recorded a loss per share of 0.04. The entity last dividend was issued on the 21st of July 2020. The firm had 1:5 split on the 10th of July 2001. Based on the measurements of operating efficiency obtained from Nova Eye's historical financial statements, Nova Eye Medical is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Nova Eye Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nova Eye has an asset utilization ratio of 78.06 percent. This implies that the Company is making USD0.78 for each dollar of assets. An increasing asset utilization means that Nova Eye Medical is more efficient with each dollar of assets it utilizes for everyday operations.Nova Eye Ownership Allocation
Nova Eye Medical maintains a total of 229.06 Million outstanding shares. Nova Eye Medical secures 18.59 % of its outstanding shares held by insiders and 18.74 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nova Eye Profitability Analysis
The company reported the revenue of 23.32 M. Net Loss for the year was (8.79 M) with profit before overhead, payroll, taxes, and interest of 14.39 M.About Nova Eye Valuation
The stock valuation mechanism determines Nova Eye's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Nova Eye Medical based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nova Eye. We calculate exposure to Nova Eye's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nova Eye's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 20.2 M | 15.5 M |
Additional Tools for Nova Stock Analysis
When running Nova Eye's price analysis, check to measure Nova Eye's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nova Eye is operating at the current time. Most of Nova Eye's value examination focuses on studying past and present price action to predict the probability of Nova Eye's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nova Eye's price. Additionally, you may evaluate how the addition of Nova Eye to your portfolios can decrease your overall portfolio volatility.